Benjamin A. Weinberg, MD
Disclosures: Eli Lilly and Company-Speaking-Speakers Bureau|Speaking-Taiho-Speakers Bureau|Bayer Corporation-Speaking-Speakers Bureau|Bayer Corporation-Honoraria-Advisory Committee|Speaking-Sirtex-Speakers Bureau|Honoraria-Speaking-HalioDx|Daiichi Sankyo-Speaking-Speakers Bureau|AstraZeneca-Speaking-Speakers Bureau - 06/25/2021

CURRICULUM VITAE

Benjamin Adam Weinberg, MD, FACP

Department of Medicine, Division of Hematology and Oncology 

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center  3800 Reservoir Road, NW 

Washington, DC 20007 

Phone: 202-444-2223, Fax: 202-444-9429 

Email: baw12@gunet.georgetown.edu

I certify that this curriculum vitae is a current and accurate statement of my professional record. Signature:___________________________ Date:___March 14, 2023____

 

 

1. PERSONAL INFORMATION 

A. Education: 

Undergraduate: University of Pennsylvania, Philadelphia, PA, USA, 2003-2007, Bachelor of  Applied Science, Biomedical Science 

Medical Education: Keck School of Medicine of the University of Southern California, Los Angeles,  CA, USA, 2007-2011, Doctor of Medicine 

Internship: MedStar Georgetown University Hospital, Internal Medicine, Washington, DC,  USA, 2011-2012, Program Director: Dr. Michael Adams 

Residency: MedStar Georgetown University Hospital, Internal Medicine, Washington, DC,  USA, 2012-2014, Program Director: Dr. Michael Adams 

Fellowship: MedStar Georgetown University Hospital, Hematology and Oncology,  Washington, DC, USA, 2014-2017, Program Director: Dr. Bruce Cheson 

B. Professional Experience: 

Associate Professor of Medicine, Department of Medicine, Division of 

Hematology and Oncology, Lombardi Comprehensive Cancer Center, 

Georgetown University Medical Center, Washington, DC, USA, 2020-present 

Assistant Professor of Medicine, Department of Medicine, Division of 

Hematology and Oncology, Lombardi Comprehensive Cancer Center, 

Georgetown University Medical Center, Washington, DC, USA, 2017-2020 

C. Licensure:

State: DC 

License No: MD040203

2

Initial Date: 2011 

Renewal/Expiration Date: 12/2024

D. Certification: 

Board Certification: Internal Medicine 

Date of Certification: 2014 

Sub-Specialty Board: Medical Oncology 

Date of Certification: 2017 

Sub-Specialty Board: Hematology 

Date of Certification: 2017 

E. Languages Spoken: English (fluent), Spanish (medical, not a native speaker) 2. RESEARCH AND SCHOLARLY ACTIVITIES 

A. Publications: 

i. Original Papers in Refereed Journals 

Xiao J, Sharma U, Arab A, Miglani S, Bhalla S, Suguru S, Suter R, Mukherji R, Lippman ME, Pohlmann  PR, Zeck JC, Marshall JL, Weinberg BA, He AR, Noel MS, Schelgel R, Agarwal S, Goodarzi H.  Propagated circulating tumor cells uncover the potential role of NFkB, EMT, TGFb signaling pathways  and COP1 in metastasis. Cancers, 2023; [in press].

Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J,  Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T,  Oberley M, Spetzler D, Korn WM, Shen L, Lenz HJ. Mutational analysis of microsatellite-stable  gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet  Oncology, 2023; epub ahead of print. doi: 10.1016/S1470-2045(22)00783-5. 

REACCT Collaborative. Post-operative functional outcomes in early age onset rectal cancer. Frontiers  Oncology, 2022 May;12:868359. doi: 10.3389/fonc.2022.868359. PubMed PMID: 35707361. PubMed  Central PMCID: PMC9190512. 

Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman RA, Ellis M,  Stafford P, Spetzler DB, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall  JL, Shields AF, Korn WM. Molecular characterization of KRAS wild type tumors in patients with

3

pancreatic adenocarcinoma. Clinical Cancer Research, 2022 Jun;28(12):2704-2714. doi: 10.1158/1078- 0432.CCR-21-3581. PubMed PMID: 35302596. 

REACCT Collaborative. Impact of microsatellite status in early-onset colonic cancer. British Journal of  Surgery, 2022 Jun;109(7):632-636. doi: 10.1093/bjs/znac108. PubMed PMID: 35522613.

Seeber A, Battaglin F, Zimmer K, Kocher F, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D,  Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA,  Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Amann A, Trajanoski Z, Berger MD, Lou E, Wolf  D, Lenz HJ. Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel  therapeutic options in colorectal cancer. Clinical Cancer Research, 2022 May;28(8):1863-1870. doi:  10.1158/1078-0432.CCR-21-3018. PubMed PMID: 35254413. PubMed Central PMCID: PMC9064897.

Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic  M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E,  Schlom J, Gulley JL, Strauss J. A randomized phase II trial of mFOLFOX6 and bevacizumab alone or  with combination immunotherapy with AdCEA vaccine plus avelumab in patients with previously  untreated metastatic colorectal cancer. The Oncologist, 2022 Mar;27(3):198-209. doi:  10.1093/oncolo/oyab046. PubMed PMID: 35274710. PubMed Central PMCID: PMC8914498. 

Weinberg BA, Winslow ER, Bayasi M, Krainock MR, Olshan PM, Billings PR, Aleshin A. Early  detection of circulating tumor DNA postoperatively enables discovery of resectable metastatic disease in  a patient with colon cancer. Case Reports in Oncology, 2021 Dec;14(3)1748-1753. doi:  10.1159/000520743. PubMed PMID: 35082635. PubMed Central PMCID: PMC8739946. 

Arai H, Elliott A, Millstein J, Xiu J, Ou F, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanish  N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E,  Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn  WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with neurofibromin 1-altered  metastatic colorectal cancer. Oncogene, 2022 Jan;41(2):260-267. doi: 10.1038/s41388-021-02074-z.  PubMed PMID: 34728807. PubMed Central PMCID: PMC8738154. 

Malchiodi ZX, Cao H, Gay MD, Safronenka A, Bansal S, Tucker RD, Weinberg BA, Cheema A,  Shivapurkar N, Smith JP. Cholecystokinin receptor antagonist improves efficacy of chemotherapy in  murine pancreatic cancer by altering tumor microenvironment. Cancers (Basel), 2021 Sep;13(10):4949.  doi: 10.3390/cancers13194949. PubMed PMID: 34638432. PubMed Central PMCID: PMC8508339.

Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ,  Philip PA, Shields AF, Marshall JL, Salem ME, Weinberg BA. Molecular characteristics of anal  squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021;12(5):2423-2437. (Co-senior  authors). doi: 10.21037/jgo-20-610.

4

Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, VanderWalde AM, Tesfaye  A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills  GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and functional characterization of atypical  KRAS/NRAS mutations in metastatic colorectal cancer. Clinical Cancer Research, 2021 Aug;27(16):4587- 4598. doi: 10.1158/1078-0432.CCR-21-0180. PubMed PMID: 34117033. PubMed Central PMCID:  PMC8364867.

Lou E, Xiu J, Baca Y, Nelson AC, Weinberg BA, Beg MS, Salem ME, Lenz HJ, Philip P, El-Deiry W,  Korn WM. Expression of immuno-oncologic biomarkers is enriched in colorectal cancers and other solid  tumors harboring the A59T variant of KRAS. Cells, May 21;10(6):1275. doi: 10.3390/cells10061275.  PubMed PMID: 3406399; PubMed Central PMCID: PMC8224072. 

Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF,  Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler  D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma  depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential  predictors of immunotherapy efficacy. Annals of Oncology, 2021 Jul;32(7):906-916. doi:  10.1016/j.annonc.2021.03.203. PubMed PMID: 33798656.

Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D,  Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart  AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM. The landscape of the DNA damage  response pathways in colorectal cancer. Clinical Cancer Research, 2021 Jun;27(11);3234-3242. doi:  10.1158/1078-0432.CCR-20-3635. PubMed PMID: 33766816.

Borden BA, Baca Y, Xiu J, Tavora F, Winer I, Weinberg BA, VanderWalde AM, Darabi S, Korn WM,  Mazar AP, Giles FJ, Crawford L, Saftran H, El-Deiry WS. The landscape of glycogen synthase kinase-3  beta (GSK-3b) genomic alterations in cancer. Molecular Cancer Therapeutics, 2021 Jan;20(1):183-190. doi: 10.1158/1535-7163.MCT_20-0497. PubMed PMID: 33087512. 

Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, Hening C, Schlenk RF, Cheema  P, Jones MR, Drilon A, Trombetta D, Muscarella LA, Tolba K, Gounant V, Cseh A, Solca F, Laskin JJ,  Renouf DJ. Therapeutic potential of afatinib in NRG1 fusion-driven solid tumors: a case series. The  Oncologist, 2021 Jul;26(1)7-16. doi: 10.1634/theoncologist.2020-0379. PMID: 32852072. PubMed  Central PMCID: PMC7794194.

Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES, Pishvaian MJ. A  phase I study of ribociclib plus everolimus in patients with metastatic pancreatic adenocarcinoma  refractory to chemotherapy. Journal of Pancreatic Cancer, 2020;6(1):1-10. doi: 

10.1089/pancan.2020.0005. PubMed Central PMCID: PMC7337242. 

Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall  JL, Brody JR. A phase I/II study of veliparib (ABT-888) in combination with 5-fluorouracil and

5

oxaliplatin in patients with metastatic pancreatic cancer. Clinical Cancer Research, 2020  Oct;26(19):5092-5101. doi: 10.1158/1078-0432.CCR-20-1301. 

 

Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns  and genomic correlates of PD-L1 expression in patients with biliary tract cancers. Journal of  Gastrointestinal Oncology, 2019 Dec;10(6):1099-1109. doi: 10.21037/jgo.2019.08.08. PubMed PMID:  31949927; PubMed Central PMCID: PMC6955012. 

Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ,  Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular  alterations and potential therapeutic targets. Journal of Gastrointestinal Oncology, 2019  Aug;10(4):652662. doi: 10.21037/jgo.2018.08.18. PubMed PMID: 31392046; PubMed Central PMCID:  PMC6657312. 

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E,  Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H,  de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival  outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis  of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the  ARCAD database. European Journal of Cancer, 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020.  Epub 2018 Sep 27. PubMed PMID: 30268921. 

Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K,  Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of patient age on molecular  alterations of the left-sided colorectal tumors. The Oncologist, 2019 Mar;24(3):319-326. doi:  10.1634/theoncologist.2018-0117. PubMed PMID: 30018131; PubMed Central PMCID: PMC6519749. 

Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Immuno-oncology biomarkers for  gastric and gastroesophageal junction adenocarcinoma: why PD-L1 testing may not be enough. The  Oncologist, 2018 Oct;23(10):1171-1177. doi: 10.1634/theoncologist.2018-0034. PubMed PMID:  29703766; PubMed Central PMCID: PMC6263127. 

Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang  JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of tumor mutation load, mismatch repair  deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Molecular Cancer  Research, 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. PubMed PMID: 29523759;  PubMed Central PMCID: PMC6833953. 

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ,  Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.  Oncotarget, 2017 Oct 17;8(49):86356-86368. doi: 10.18632/oncotarget.21169. PubMed PMID:  29156800; PubMed Central PMCID: PMC5689690. (Co-first authors). 

Weinberg BA, Gowen K, Lee TK, Ou SH, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA,  Liu SV, Klempner SJ. Comprehensive genomic profiling aids in distinguishing metastatic recurrence

6

from second primary cancers. The Oncologist, 2017 Feb;22(2):152-157. doi: 

10.1634/theoncologist.20150511. PubMed PMID: 28193735; PubMed Central PMCID: PMC5330711. 

Weinberg BA, Wang H, Yang X, Wu CS, Pishvaian MJ, He AR, Marshall JL, Hwang JJ. Maintenance  therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy, a  retrospective cohort study. Gastrointestinal Cancer Research, 2014 May;7(3-4):91-97. PubMed PMID:  25276262; PubMed Central PMCID: PMC4171974. 

El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G, Rosas IO, Aparicio  M, Ren P, MacDonald SD, Wu HP, Nathan SD, Cuttitta F, McCoy JP, Gochuico BR, Moss J. Abnormal  lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular  mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2009  Mar;106(10):3958-3963. doi: 10.1073/pnac.0813368106. PubMed PMID: 19237567; PubMed Central  PMCID: PMC2646625. 

ii. Reviews or Editorials in Refereed Journals 

Mukherji R, Yin C, Hameed R, Alqahtani AZ, Kulasekaran M, He AR, Weinberg BA, Marshall JL, Hartley  ML, Noel MS. The current state of molecular profiling in gastrointestinal malignancies. Biology Direct,  2022 Jun;17(1):15. doi: 10.1186/s13062-022-00322-0. PubMed PMID: 35668531. PubMed Central  PMCID: PMC9172079.

Mukherji R, Weinberg BA, Pedersen KS. Immunotherapy for colorectal cancer. Hematology/Oncology  Clinics of North America, 2022 Jun;36(3):603-626. doi: 10.1016/j.hoc.2022.02.010. PubMed PMID:  35577706.

Mukherji R, Alqahtani A, Winters HD, Weinberg BA. The use of ctDNA to assess minimal residual disease  in gastrointestinal cancers. touchREVIEWS in Oncology & Hematology, 2022 May;18(1):26-39. doi:  10.17925/OHR.2022.18.1.26.

Xiao J, Pohlmann PR, Issacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating tumor cells:  technologies and their clinical potential in cancer metastasis. Biomedicines, 2021 Aug;9(9):1111. doi:  10.3390/biomedicines9091111. PubMed PMID: 34572297. PubMed Central PMCID: PMC8467892.

REACCT Collaborative, Zaborowski AM, Abdile A, Adamina M, Aigner F, d'Allens L, Allmer C,  Álvarez A, Anula R, Andric M, Atallah S, Bach S, Bala M, Barussaud M, Bausys A, Bebington B, Beggs  A, Bellolio F, Bennett MR, Berdinskikh A, Bevan V, Biondo S, Bislenghi G, Bludau M, Boutall A,  Brouwer N, Brown C, Bruns C, Buchanan DD, Buchwald P, Burger JWA, Burlov N, Campanelli M,  Capdepont M, Carvello M, Chew HH, Christoforidis D, Clark D, Climent M, Cologne KG, Contreras T,  Croner R, Daniels IR, Dapri G, Davies J, Delrio P, Denost Q, Deutsch M, Dias A, D'Hoore A, Drozdov E,  Duek D, Dunlop M, Dziki A, Edmundson A, Efetov S, El-Hussuna A, Elliot B, Emile S, Espin E, Evans  M, Faes S, Faiz O, Fleming F, Foppa C, Fowler G, Frasson M, Figueiredo N, Forgan T, Frizelle F,  Gadaev S, Gellona J, Glyn T, Gong J, Goran B, Greenwood E, Guren MG, Guillon S, Gutlic I, Hahnloser  D, Hampel H, Hanly A, Hasegawa H, Iversen LH, Hill A, Hill J, Hoch J, Hoffmeister M, Hompes R,

7

Hurtado L, Iaquinandi F, Imbrasaite U, Islam R, Jafari MD, Kanemitsu Y, Karachun A, Karimuddin AA,  Keller DS, Kelly J, Kennelly R, Khrykov G, Kocian P, Koh C, Kok N, Knight KA, Knol J,  Kontovounisios C, Korner H, Krivokapic Z, Kronberger I, Kroon HM, Kryzauskas M, Kural S, Kusters  M, Lakkis Z, Lankov T, Larson D, Lázár G, Lee KY, Lee SH, Lefèvre JH, Lepisto A, Lieu C, Loi L,  Lynch C, Maillou-Martinaud H, Maroli A, Martin S, Martling A, Matzel KE, Mayol J, McDermott F,  Meurette G, Millan M, Mitteregger M, Moiseenko A, Monson JRT, Morarasu S, Moritani K, Möslein G,  Munini M, Nahas C, Nahas S, Negoi I, Novikova A, Ocares M, Okabayashi K, Olkina A, Oñate-Ocaña L,  Otero J, Ozen C, Pace U, São Julião GP, Panaiotti L, Panis Y, Papamichael D, Park J, Patel S, Patrón  Uriburu JC, Pera M, Perez RO, Petrov A, Pfeffer F, Phang PT, Poskus T, Pringle H, Proud D, Raguz I,  Rama N, Rasheed S, Raval MJ, Rega D, Reissfelder C, Reyes Meneses JC, Ris F, Riss S, Rodriguez Zentner H, Roxburgh CS, Saklani A, Salido AJ, Sammour T, Saraste D, Schneider M, Seishima R,  Sekulic A, Seppala T, Sheahan K, Shine R, Shlomina A, Sica GS, Singnomklao T, Siragusa L, Smart N,  Solis A, Spinelli A, Staiger RD, Stamos MJ, Steele S, Sunderland M, Tan KK, Tanis PJ, Tekkis P, Teklay  B, Tengku S, Jiménez-Toscano M, Tsarkov P, Turina M, Ulrich A, Vailati BB, van Harten M, Verhoef K,  Warrier S, Wexner S, de Wilt H, Weinberg BA, Wells C, Wolthuis A, Xynos E, You N, Zakharenko A,  Zeballos J, Winter DC. Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA  Surgery, 2021 Sep;156(9):865-874. doi: 10.1001/jamasurg.2021.2380. PubMed PMID: 34190968. 

Armstrong SA, Malley R, Weinberg BA. Molecular profiling in metastatic colorectal cancer. Oncology  (Williston Park), 2020 Sep;34(9):352-355. doi: 10.46883/ONC.2020.3409.0352. PubMed PMID:  32965665. 

Armstrong SA, Malley R, Weinberg BA. Glimmers of hope: new strategies for overcoming resistance in  patients with BRAF V600E-mutated metastatic colorectal cancer. Oncology & Hematology Review (US),  2020 Jul;16(1):31-35. 

Mukherji R, Weinberg BA. The gut microbiome and potential implications for early-onset colorectal  cancer. Colorectal Cancer, 2020 Oct;9(3). doi: 10.2217/crc-2020-0007. 

Marshall JL, Yarden RI, Weinberg BA. Colorectal cancer in the age of coronavirus – strategies to reduce  risk and maintain benefit. Colorectal Cancer, 2020 Apr;9(1). doi: 10.2217/crc-2020-0010. PubMed  Central PMCID: PMC7170009. 

Weinberg BA, Hameed R, Marshall JL. Biomarkers for immune therapy in gastrointestinal cancers.  Clinical Advances in Hematology & Oncology, 2019 Feb;17(2):109-119. PubMed PMID: 30845114. 

Weinberg BA, Marshall JL. Colon cancer in young adults: trends and their implications. Current  Oncology Reports, 2019 Jan 18;21(1):3. doi: 10.1007/s11912-019-0756-8. PubMed PMID: 30659375. 

Weinberg BA. Anti-EGFR therapy in right-sided metastatic colorectal cancer: right or wrong? Journal of  the National Comprehensive Cancer Network, 2018 Dec;16(12):1547-1548. doi:  10.6004/jnccn.2018.7107. PubMed PMID: 30545999. 

Puthiamadathil JM, Weinberg BA. Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. Cancer Management and Research, 2017 Oct;9:461-469. doi:

8

10.2147/CMAR.S113320. PubMed PMID: 29056855; PubMed Central PMCID: PMC5635852. 

Serzan MT, Weinberg BA, Salem ME. Second-line therapy in advanced colorectal cancer: EGFR vs.  continuation of VEGF inhibition. Current Colorectal Cancer Reports, 2017 Sep 18;13(6):411-418. doi:  10.1007/s11888-017-0388-z. 

Weinberg BA, Hartley M, Salem ME. Precision medicine in metastatic colorectal cancer: relevant  carcinogenic pathways and targets. Part 1: biologic therapy targeting epidermal growth factor receptor  and vascular endothelial growth factor. Oncology (Williston Park), 2017 Jul;31(7):539-548. PubMed  PMID: 28712098. 

Weinberg BA, Hartley M, Salem ME. Precision medicine in metastatic colorectal cancer: relevant  carcinogenic pathways and targets. Part 2: approaches beyond first-line therapy, and novel biologic agents  under investigation. Oncology (Williston Park), 2017 Jul;31(7):573-580. PubMed PMID: 28712102. 

Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer.  Oncology (Williston Park), 2017 May;31(5):381-389. PubMed PMID: 28516436. 

Weinberg BA, Philip PA, Salem ME. Evolving standards of care for resected pancreatic cancer. Clinical  Advances in Hematology & Oncology, 2017 Feb;15(2):141-150. PubMed PMID: 28398285. 

Weinberg BA, Marshall JL, Salem ME. Trifluridine/tipiracil and regorafenib: new weapons in the war  against metastatic colorectal cancer. Clinical Advances in Hematology & Oncology, 2016  Aug;14(8):630638. PubMed PMID: 27487107. 

Weinberg BA, Marshall JL, Hartley M, Salem ME. A paradigm shift from one-size-fits-all to tailor-made  therapy for metastatic colorectal cancer. Clinical Advances in Hematology & Oncology, 2016  Feb;14(2):116-128. PubMed PMID: 27057810. 

Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ. Current standards and novel treatment options for  metastatic pancreatic adenocarcinoma. Oncology (Williston Park), 2015 Nov;29(11):809-820, 886.  PubMed PMID: 26573060. 

iii. Books or Chapters in Books 

Weinberg BA, Jawed I, Marshall JL. “Anal Cancer.” Hematology-Oncology Therapy, Third Edition.  Eds. Michael M. Boyiadzis, Tito Fojo, and David R. Kohler. Columbus: McGraw-Hill, 2022. doi:  10.1007/978-1-260-11740-5. 

Singh BP, Weinberg BA, Kim SS, Marshall JL. “Systemic Therapy for Colorectal Cancer Liver  Metastases: Sorting Through the Options.” Colorectal Cancer Liver Metastases. Eds. Mauro Monteiro  Correia, Michael Choti, Flavio G. Rocha, and Go Wakabayashi. Philadelphia: Springer, 2020. 185-203.  doi: 10.1007/978-3-030-25486-5_15. 

Salem ME, Weinberg BA, Abdul Khalek FJ, Desai JR, Warner EA, Hartley ML, Marshall JL.

9

“Metastatic Colorectal Cancer.” Textbook of Gastrointestinal Oncology. Eds. Suayib Yalcin and Philip A.  Philip. Philadelphia: Springer, 2019. 135-160. doi: 10.1007/978-3-030-18890-0_8. 

Weinberg BA, Pishvaian MJ. “Vaccine Therapy in Pancreatic Cancer.” Current and Emerging Therapies  in Pancreatic Cancer. Eds. Tanios Bekaii-Saab and Bassel El-Rayes. Philadelphia: Springer, 2018.  281307. doi: 10.1007/978-3-319-58256-6_16. 

Weinberg BA. “Carcinoma of Unknown Primary.” Hoffman and Abeloff’s Hematology-Oncology  Review, First Edition. Ed. Claudine Isaacs. Philadelphia: Elsevier, 2017. 223-227. doi: 10.1007/978- 0323-42975-7_30. 

Roesch E, Weinberg BA. “Survivorship and Treatment-Related Issues.” Hoffman and Abeloff’s  Hematology-Oncology Review, First Edition. Ed. Claudine Isaacs. Philadelphia: Elsevier, 2017. 376-385.  doi: 10.1007/978-0-323-42975-7_37. 

Heery CR, Tesfaye AA, Weinberg BA, Marshall JL. “Therapeutic Cancer Vaccines.” Immunotherapy for  Gastrointestinal Cancer. Eds. David Kerr and Rebecca Johnson. Philadelphia: Springer, 2017. 47-78. doi:  10.1007/978-3-319-43063-8_3. 

iv. Other Publications 

Weinberg BA. The role of microbiota and its impact on the tumor microenvironment in colorectal cancer.  Immunoscore E-news, May 2020.

v. Abstracts for Conference papers and posters 

Oral presentation at the ASCO Annual Meeting 2022: Schram AM, Goto K, Kim D-W, Martin-Romano  P, Ou SI, O’Kane GM, O’Reilly EM, Umemoto K, Duruisseaux M, Neuzillet C, Opdam F, Ahnert JR,  Nagasaka M, Weinberg BA, Macarulla T, Joe AK, Ford J, Stalbovskaya V, Wasserman E, Drilon AE.  Efficacy and safety of zenocutuzumab, a HER2 X HER3 bispecific antibody, across advanced NRG1  fusion (NRG1+) cancers. Journal of Clinical Oncology, 40(16_suppl):abstract 105. doi:  10.1200/JCO.2022.40.16_suppl.105.

Poster presentation at the ASCO Annual Meeting 2022: Alqahtani A, Dykes K, Yin C, Geng X, Wang H,  Weinberg BA. Outcomes in patients undergoing curative surgery for gastric cancer by facility type and  socioeconomic factors: an analysis of the National Cancer Database. Journal of Clinical Oncology,  40(16_suppl):abstract 4066. doi: 10.1200/JCO.2022.40.16_suppl.4066.

Online presentation from the ASCO Annual Meeting 2022: Stuhlmiller TJ, Cohen S, Jain SK, Nair S,  Weinberg BA, Ginn S, Wood A, Knoerzer D, Box JA, Federowicz B, Kesari S. Updated clinical  outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).  Journal of Clinical Oncology, 40(16_suppl):abstract e15101. doi: 

10.1200/JCO.2022.40.16_suppl.315101.

Poster presentation at the ASCO Annual Meeting 2022: Bessudo A, Cohen EEW, Gutierrez R, Johnson  DH, Rosenberg A, Weinberg BA, Ulahannan SV, Reuveni H, Schickler M, Liang BC. Interim safety and

10

efficacy results form a phase 1 study of NT219 in adults with advanced solid tumors. Journal of Clinical  Oncology, 40(16_suppl):abstract 3096. doi: 10.1200/JCO.2022.40.16_suppl.3096.

Poster presentation at the ASCO Annual Meeting 2022: Soni S, Battaglin F, Baca Y, Xiu J, Brodskiy P,  Lo JH, Algaze S, Jayachandran P, Arai H, Zhang W, Weinberg BA, Lou E, Gulhati P, Khushman M,  Shields AF, Goldberg RM, Marshall J, Korn WM, Lenz HJ. Molecular correlates of MAEA expression in  colorectal cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3128. doi:  10.1200/JCO.2022.40.16_suppl.3128.

Poster presentation at the ASCO Annual Meeting 2022: Algaze S, Baca Y, Brodskiy P, Xiu J, Battaglin F,  Yang Y, Millstein J, Jayachandran P, Arai H, Soni S, Zhang W, Goldberg RM, Weinberg BA, Lou E,  Shields AF, Marshall J, WM Korn, Lenz HJ. Characterization of TIM3 and its ligands in colorectal  cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3547. doi: 

10.1200/JCO.2022.40.16_suppl.3547.

Poster presentation at the ASCO Annual Meeting 2022: Lenz A, Zeng J, Xiu J, Algaze S, Jayachandran P,  Soni S, Lo JH, Arai H, Zhang W, Brodskiy P, Gulhati P, Weinberg BA, Lou E, Shields AF, Goldberg  RM, Marshall J, Korn WM, Lenz HJ, Torres ETR, Battaglin F. Characterization of NY-ESO-1 gene  expression in gastric cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 4046. doi:  10.1200/JCO.2022.40.16_suppl.4046.

Poster presentation at the ASCO Annual Meeting 2022: Lenz A, Zeng J, Xiu J, Algaze S, Jayachandran P,  Soni S, Lo JH, Arai H, Zhang W, Brodskiy P, Hosein PJ, Weinberg BA, Lou E, Shields AF, Goldberg  RM, Marshall J, Korn WM, Lenz HJ, Battaglin F, Torres ETR. Claudin 18 gene expression and related  molecular profile in gastric cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 4048. doi:  10.1200/JCO.2022.40.16_suppl.4048.

Poster presentation at the ASCO Annual Meeting 2022: Battaglin F, Baca Y, Brodskiy P, Xiu J,  Jayachandran P, Algaze S, Arai H, Soni S, Torres ETR, Mumenthaler SM, Zhang W, Goldberg RM,  Weinberg BA, Lou E, Shields AF, Marshall J, Korn WM, Kay SA, Lenz HJ. Comprehensive profiling of  clock genes expression in colorectal cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3129.  doi: 10.1200/JCO.2022.40.16_suppl.3129.

Poster presentation at the ASCO Annual Meeting 2022: Arai H, Elliott A, Farrell A, Wang J, Battaglin F,  Kawanishi N, Jayachandran P, Soni S, Wu Z, Sohal DPS, Goldberg RM, Hall MJ, Scott AJ, Khushman  M, Hwang JJ, Lou E, Weinberg BA, Marshall J, Korn WM, Lenz HJ. Landscape of endocytosis pathway  in colorectal cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3148. doi:  10.1200/JCO.2022.40.16_suppl.3148.

Poster presentation at the ASCO Annual Meeting 2022: Lo HJ, Battaglin F, Baca Y, Xiu J, Brodskiy P,  Algaze S, Jayachandran P, Arai H, Zhang W, Weinberg BA, Shroff RT, Sohal DPS, Lou E, Shields AF,  Goldberg RM, Marshall J, Korn WM, Soni S, Lenz HJ. DEFB1 gene expression and the molecular  landscape of colorectal cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3523. doi:  10.1200/JCO.2022.40.16_suppl.3523.

11

Poster presentation at the ASCO Annual Meeting 2022: Battaglin F, Xiu J, Brodskiy P, Algaze S,  Jayachandran P, Arai H, Soni S, Zhang W, Weinberg BA, Lou E, Shields AF, Goldberg RM, Marshall J,  Korn WM, Lenz HJ. Comprehensive characterization of PTPRT expression in colorectal cancer. Journal of Clinical Oncology, 40(16_suppl):abstract 3538. doi: 10.1200/JCO.2022.40.16_suppl.3538.

Poster presentation at the ASCO Annual Meeting 2022: Gholami S, Baca Y, Brodskiy P, Xiu J, Manji  GA, Seeber A, Saeed A, Weinberg BA, Khushman MM, Shroff RT, Abraham J, Shields AF, Lenz HJ,  Marshall J, Korn WM, Lou E. CXCR4 overexpression: an indicator of poor survival and predictor of  response to immunotherapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology,  40(16_suppl):abstract 3546. doi: 10.1200/JCO.2022.40.16_suppl.3546.

Oral presentation at the Gastrointestinal Cancers Symposium 2022: Battaglin F, Elliott A, Stafford P,  Helmstetter A, Oberley MJ, Arai H, Jayachandran P, Kawanishi N, Soni S, Lo HJ, Zhang W, Weinberg  BA, Lou E, Shields AF, Spetzler D, Goldberg RM, Marshall J, Korn WM, Lenz HJ. Identification and  characterization of recurrent neoantigens in upper gastrointestinal cancers. Journal of Clinical Oncology,  40(4_suppl):abstract 246. doi: 10.1200/JCO.2022.40.4_suppl.246.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Alqahtani A, Alloghbi A, Yin C,  Mukherji R, Weinberg BA. Prognostic utility of preoperative and postoperative circulating tumor DNA  in resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Journal of Clinical  Oncology, 40(4_suppl):abstract 595. doi: 10.1200/JCO.2022.40.4_suppl.595.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Abdelrahim M, Kasi A, Baca Y,  Xiu J, Walker P, Korn WM, Lou E, Shields AF, Weinberg BA. Comparative molecular profiling of  pancreatic ductal adenocarcinoma of the head versus body/tail and the tumor immune microenvironment. Journal of Clinical Oncology, 40(4_suppl):abstract 598. doi: 10.1200/JCO.2022.40.4_suppl.598.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Armstrong SA, Wang HJ, Liu G-H,  Arieta C, Thomas M, Geng S, Fritz Z, He AR, Noel MS, Weinberg BA, Marshall J. Feasibility of  acupressure intervention to improve chemotherapy-related symptoms and functioning among  gastrointestinal cancer patients. Journal of Clinical Oncology, 40(4_suppl):abstract 657. doi:  10.1200/JCO.2022.40.4_suppl.657.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Ahn DH, Ou F-S, Sonbol BB,  Wender D, Klute K, Jin Z, Jones JC, Ulrich A, Waechter B, Young H, Weinberg BA, Lenz HJ, Strickler  JH, Bekaii-Saab TS. REVERCEII (ACCRU-GI-1809): a randomized phase II study of regorafenib  followed by anti-EGFR monoclonal antibody therapy versus the reverse sequence for metastatic  colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan. Journal of  Clinical Oncology, 40(4_suppl):abstract TPS213. doi: 10.1200/JCO.2022.40.4_suppl.TPS213.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Jayachandran P, Yin J, Xiu J,  Brodskiy P, Arai H, Abraham J, Battaglin F, Soni S, Hall MJ, Khushman MM, Sohal D, Weinberg BA, Goldberg RM, Lou E, Zhang W, Millstein J, Korn WM, Lenz HJ. LRP1B and GRM3 expression in  colorectal cancer. Journal of Clinical Oncology, 40(4_suppl):abstract 177. doi: 

10.1200/JCO.2022.40.4_suppl.177.

12

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Yin C, Armstrong SA, Agarwal S,  Wang H, Noel MS, Weinberg BA, Marshall J, He AR. Phase II study of combination pembrolizumab  and olaparib in patients with advanced cholangiocarcinoma: interim results. Journal of Clinical Oncology,  40(4_suppl):abstract 452. doi: 10.1200/JCO.2022.40.4_suppl.452.

Poster presentation at the Gastrointestinal Cancers Symposium 2022: Yin C, Marshall J, Macke L, Bouker  K, He AR, Weinberg BA, Weiner LM, Wang H, Badri N, Biswas-Baldwin N, Hoke F, Youssoufian H,  El-Hariry I, Noel MS. A phase I dose-escalation study of eryaspase in combination with modified  FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: interim update.  Journal of Clinical Oncology, 40(4_suppl):abstract 581. doi: 10.1200/JCO.2022.40.4_suppl.581.

Oral presentation at the ESMO 22nd World Congress on Gastrointestinal Cancer, 2020: Redman JM, Tsai  YT, Donahue RN, Gandhy S, Gatty-Mays ME, Abdul-Sater H, Cordes LM, Steinberg S, Marte JL,  McMahon S, Kim S, Marshall JL, Weinberg BA, Schlom J, Gulley JL, Strauss J. A randomized phase II  trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab  in patients with previously untreated metastatic colorectal cancer (mCRC). Annals of Oncology, [in  press]. 

Oral presentation at the ASCO Annual Meeting 2021: Weinberg BA, “Novel systemic approaches for  metastatic pancreatic cancer,” abstract discussant.

Poster presentation at the ASCO Annual Meeting 2020: Weinberg BA, Wang H, He AR, Villa N, Unger  KR. Phase I study of proton therapy in adjuvant pancreatic cancer (PROTON-PANC). Journal of Clinical  Oncology, 38(15_suppl):abstract TPS4663. doi: 10.1200/JCO.2020.38.15_suppl.TPS4663. 

Poster presentation at the ASCO Annual Meeting 2020: He AR, Weinberg BA, Noel MS, Milic VP, Prins P, Wang H, Hartley ML, Marshall J. Phase II study of pembrolizumab plus olaparib in the treatment of  patients with advanced cholangiocarcinoma. Journal of Clinical Oncology, 38(15_suppl):abstract  TPS4659. doi: 10.1200/JCO.2020.38.15_suppl.TPS4659. 

Poster presentation at the ASCO Annual Meeting 2020: Wang J, Xiu J, Shields AF, Grothey A,  Weinberg BA, Marshall J, Lou E, Khushman MM, Sohal D, Hall MJ, Battaglin F, Arai H, Soni S, Zhang  W, Korn WM, Lenz HJ. Comprehensive molecular analysis of microsatellite-stable tumors with high  mutational burden in gastrointestinal cancers. Journal of Clinical Oncology, 38(15_suppl):abstract 3631.  doi: 10.1200/JCO.2020.38.15_suppl.3631. 

Poster presentation at the ASCO Annual Meeting 2020: Wang J, Xiu J, Shields AF, Grothey A,  Weinberg BA, Marshall J, Lou E, Khushman MM, Sohal D, Hall MJ, Battaglin F, Arai H, Soni S, Zhang  W, Korn WM, Lenz HJ. Molecular correlates of PD-L1 expression in patients with gastroesophageal  cancer. Journal of Clinical Oncology, 38(15_suppl):abstract 4558. doi: 

10.1200/JCO.2020.38.15_suppl.4558. 

Poster presentation at the ASCO Annual Meeting 2020: Stein MK, Elliott A, Hwang JJ, Lou E,  Khushman MM, Scott AJ, Marshall J, Sohal D, Weinberg BA, Goldberg RM, Salem ME, Korn WM,  Grothey A. (2020) The landscape of MAP3K1/MAP2K4 alterations in gastrointestinal malignancies.

13

Journal of Clinical Oncology, 38(15_suppl):abstract 4113. doi: 10.1200/JCO.2020.38.15_suppl.4113. 

Poster presentation at the ASCO Annual Meeting 2020: Philip PA, Xiu J, Hall MJ, Hendifar AE, Lou E,  Hwang JJ, Gong J, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, Marshall J, Grothey A,  Shields AF, Korn WM. (2020) Enrichment of alterations in targetable molecular pathways in KRAS  wildtype pancreatic cancer. Journal of Clinical Oncology, 38(15_suppl):abstract 4629. doi:  10.1200/JCO.2020.38.15_suppl.4629. 

Poster presentation at the AACR Annual Meeting 2020: Malchiodi Z, Cao H, Gay M, Bansal S,  Weinberg BA, Cheema A, Shivapurkar N, Smith JP. Cholecystokinin receptor antagonist decreases  fibrosis in pancreatic cancer microenvironment to improve uptake and efficacy of chemotherapy. Cancer  Research, [in press]. 

Poster presentation at the AACR Annual Meeting 2020: Weinberg BA, Wang H, Witkiewicz AK,  Marshall JL, He AR, Knudsen ES, Pishvaian MJ. A phase I study of ribociclib plus everolimus in patients  with metastatic pancreatic adenocarcinoma refractory to chemotherapy. Cancer Research.

Poster presentation at the Gastrointestinal Cancers Symposium 2020: Weinberg BA, Wang H, Geng X,  Shokrolla S, Bakhshi E, Chaldekas K, Harris BT, Clagett D, Marshall JL. A comparison study of  intratumoral microbiome in younger versus older-onset colorectal cancer. Journal of Clinical Oncology,  2020 Feb 1;38(suppl_4):abstract 241. doi: 10.1200/JCO.2020.38.4_suppl.241. 

Poster presentation at the Gastrointestinal Cancers Symposium 2020: Weinberg BA, Wang H, Pedersen  K, Sehdev A, Sung MW, Hwang JJ. Phase II study of fluorouracil, leucovorin, and nanoliposomal  irinotecan in previously treated advanced biliary tract cancer (NAPOLI-2). Journal of Clinical Oncology,  2020 Feb1;38(4_suppl):abstract TPS593. doi: 10.1200/JCO.2020.38.4_suppl.TPS593. 

Poster presentation at the Gastrointestinal Cancers Symposium 2020: Singh BP, Ballman M, Drake E,  Khanchandani A, Prins P, Weinberg BA. Platinum-based therapy of patients with gastrointestinal cancers  that harbor homologous recombination DNA damage response mutations: a single institutional  retrospective analysis. Journal of Clinical Oncology, 2020 Feb 1;38(4_suppl):abstract 836. doi:  10.1200/JCO.2020.38.4_suppl.836. 

Poster presentation at the ESMO Asia Congress 2019: Goto Y, Cadranel J, Weinberg BA, Duruisseaux  M, Liu SV, Tolba K, Branden E, Doebele RC, Heining C, Schlenk RF, Laskin JJ, Cheema PK, Jones MR,  Trombetta D, Muscarella LA, Cseh A, Solca F, Renouf DJ. NRG1-fusion-driven solid tumors: a case  series indicating the therapeutic potential of afatinib. Annals of Oncology, 2019 Nov;30(suppl_9):  abstract 63O. doi: 10.1093/annonc/mdz420.002. 

Poster presentation at the ASCO Breakthrough Summit 2019: Laskin JJ, Cadranel J, Renouf DJ,  Weinberg BA, Goto Y, Duruisseaux M, Tolba K, Branden E, Doebele RC, Heining C, Schlenk RF,  Cheema PK, Jones MR, Trombetta D, Muscarella LA, Cseh A, Solca F, Liu SV. Afatinib as a novel  treatment option for NRG1 fusion-positive tumors. Journal of Global Oncology, 2019 Oct  7;5(suppl):abstract 110. doi: 10.1200/JGO.2019.5.suppl.110. 

Poster presentation at the ESMO Congress 2019: Liu SV, Duruisseaux M, Tolba K, Branden E, Goto Y,

14

Weinberg BA, Renouf DJ, Doebele RC, Heining C, Schlenk RF, Cheema PK, Cadranel J, Jones MR,  Drilon AE, Trombetta D, Muscarella LA, Cseh A, Solca F, Laskin JJ. Targeting NRG1-fusions in  multiple tumour types: afatinib as a novel potential treatment option. Annals of Oncology, 2019 Sep  30;30(suppl_5):abstract 1969P. doi: 10.1093/annonc/mdz268.096. 

Poster presentation at the CSCO Congress 2019: Liu SV, Duruisseaux M, Tolba K, Branden E, Goto Y,  Weinberg BA, Doebele RC, Heining C, Schlenk RF, Cheema PK, Cadranel J, Jones MR, Drilon AE,  Cseh A, Solca F, Laskin JJ. NRG1 fusion-positive (NRG1+) tumours: afatinib as a novel potential  treatment option. 2019 Sep. 

Poster presentation at the ESMO 21st World Congress on Gastrointestinal Cancer, 2019: Weinberg BA,  Renouf D, Lim H, Heining C, Schlenk RF, Jones MR, Liu SV, Cseh A, Solca F, Laskin JJ. NRG1 fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option. Annals of Oncology,  2019 Jul;30(Supplement 4):abstract P-291. doi: 10.1093/annonc/mdz155.290. 

Poster presentation at the ASCO Annual Meeting 2019: Pishvaian MJ, Wang H, Parenti S, He AR,  Hwang JJ, Ley L, DiFebo H, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR.  Final report of a phase I/II study of veliparib in combination with 5-FU and oxaliplatin (FOLFOX) in  patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2019 May  20;37(15_suppl):abstract 4015. doi: 10.1200/JCO.2019.37.15_suppl.4015. 

Poster presentation at the Gastrointestinal Cancers Symposium 2019: Doyle A, Kubler MM, Harris AC,  López A, Govindaraj P, Prins P, Weinberg BA. The impact of CDKN2A mutations on overall survival in  pancreatic adenocarcinoma. Journal of Clinical Oncology, 2019 Feb 1;37(4_suppl):abstract 278. doi:  10.1200/JCO.2019.37.4_suppl.278. 

Poster presentation at the ASCO Annual Meeting 2018: Weinberg BA, Wang H, Witkiewicz AK,  Marshall JL, Knudsen ES, Pishvaian MJ. A phase I/II study of ribociclib plus everolimus in patients with  metastatic pancreatic adenocarcinoma refractory to chemotherapy. Journal of Clinical Oncology, 2018  May 20;36(15_suppl):abstract TPS4150. doi: 10.1200/JCO.2018.36.15_suppl.TPS4150. 

Poster presentation at the ASCO Annual Meeting 2018: Trivedi N, Feldman R, Wang H, Karki NR,  Marshall JL, Weinberg BA. Comprehensive molecular profiling of paired samples of primary and  metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology, 2018 May  20;36(15_suppl):abstract 4114. doi: 10.1200/JCO.2018.36.15_suppl.4114. 

Poster presentation at the Gastrointestinal Cancers Symposium 2018: Roshad N, Heeke AL, Khaled HM,  Ali El Din NH, Abd El Motaal G, Weinberg BA, Wang H, Salem ME. Impact of age on clinical and  pathological features as well as outcome in Egyptian patients with colorectal cancer. Journal of Clinical  Oncology, 2018 Feb 1;36(4_suppl):abstract 600. doi: 10.1200/JCO.2018.36.4_suppl.600. 

Poster presentation at the ESMO Congress 2017: Heeke AL, Roshad N, Khaled HM, Ali El Din NH, Abd  El Motaal G, Weinberg BA, Wang H, Salem ME. Variations in clinicopathological features, treatment  patterns, and outcomes of young adults with colorectal cancer in the United States and Egypt. Annals of  Oncology, 2017 Sep 9;28(suppl_5):abstract 608P. doi: 10.1093/annonc/mdx393.133.

15

Poster presentation at the ASCO Annual Meeting 2017: Weinberg BA, Poorman K, Arguello D, Marshall  J, Salem ME. Impact of patient age on molecular alterations in left-sided colorectal tumors.  Journal of Clinical Oncology, 2017 May 20;35(15_suppl):abstract 3592. doi: 

10.1200/JCO.2017.35.15_suppl.3592.

Poster presentation at the Gastrointestinal Cancers Symposium 2017 and the MedStar Health Research  Symposium 2017: Salem ME, Xiu J, Weinberg BA, El-Deiry WS, Weiner LM, Gatalica Z, Liu Z, El  Ghazaly H, Xiao N, Hwang JJ, Philip PA, Shields AF, Lenz HJ, Marshall J. Characterization of tumor  mutational burden in gastrointestinal cancers. Journal of Clinical Oncology, 2017 Feb  1;35(4_suppl):abstract 530. doi: 10.1200/JCO.2017.35.4_suppl.530. 

Poster presentation at the Gastrointestinal Cancers Symposium 2017 and the MedStar Health Research  Symposium 2017: Weinberg BA, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Liu Z, Chen S,  El Ghazaly H, Hwang JJ, Philip PA, Shields AF, Marshall J, Salem ME. Molecular characterization of  squamous cell carcinoma of the anal canal. Journal of Clinical Oncology, 2017 Feb 1;35(4_suppl):abstract  538. doi: 10.1200/JCO.2017.35.4_suppl.538. 

Poster presentation at the Gastrointestinal Cancers Symposium 2017: Salem ME, Yin J, Renfro LA,  Weinberg BA, Maughan T, Adams R, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio  E, Aranda E, Bokemeyer C, Heinemann V, De Gramont A, Grothey A, Marshall J, Sargent DJ. Rectal  versus left-sided colon cancers: clinicopathological differences observed in a pooled analysis of 4,182  patients enrolled to 8 clinical trials from the ARCAD database. Journal of Clinical Oncology, 2017 Feb  1;35(4_suppl):abstract 675. doi: 10.1200/JCO.2017.35.4_suppl.675. 

Poster presentation at the European Society for Medical Oncology Congress 2014: Apolo AB, Bottaro  DP, Merino MJ, Xi L, Lee YH, Weinberg BA, Wright JJ, Dahut WL, Parnes HL, Raffeld M. Met tumor  expression and mutational analysis in bladder cancer patients receiving cabozantinib. Annals of  Oncology, 2014 Sep 1;25(Suppl_4):iv281. doi: 10.1093/annonc/mdu337.4. 

Poster presentation at the Genitourinary Cancers Symposium 2014: Weinberg BA, Lindenberg ML,  Kurdziel KA, Steinberg SM, Liewehr DJ, Khadar K, McKinney Y, Choyke PL, Apolo AB. Assessment of  bone metastases in patients with urothelial carcinoma using 18F-sodium fluoride PET/CT(18F-NaF) versus  18F-fluorodeoxyglucose PET/CT (18F-FDG). Journal of Clinical Oncology, 2014 Feb  1;32(4_suppl):abstract 329. doi: 10.1200/JCO.2014.32.4_suppl.329. 

Selected for the ASCO Annual Meeting 2012: Xuezhong AY, Weinberg BA, Hwang JJ, Wu CS, Akram  M, Pishvaian MJ, He AR, Marshall JL. Survival analysis of maintenance capecitabine in patients with  resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study. Journal of  Clinical Oncology, 2012;30(15_suppl):abstract e14658. 

Poster presentation at the Gastrointestinal Cancers Symposium 2012: Xuezhong AY, Wu CS, Hwang JJ,  Weinberg BA, Pishvaian MJ, He AR, Marshall JL. Maintenance therapy with capecitabine in patients  with resected pancreatic adenocarcinoma after adjuvant therapy. Journal of Clinical Oncology, 2012 Feb  1;30(4_suppl):abstract 333. doi: 10.1200/jco.2012.30.4_suppl.333.

16

Poster presentation at the Combined Meeting of the Connective Tissue Oncology Society and the  Musculoskeletal Tumor Society 2011: Weinberg BA, Hu JS. Primary pulmonary artery sarcoma treated  with doxorubicin and docetaxel: a case report. 

B. Research Funding: 

i. Current Active 

Agency: Pancreatic Cancer Action Network 

Identifying Number: Pancreatic Cancer Action Network Translational Research Grant  Title of Project: Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in  Pancreatic Cancer 

Dates of Project Period: 2020-2022 

Corresponding PI: Jill P. Smith, Co-PI: Weinberg 

Total Direct Costs over all years of award: $452,658 

Total Indirect Costs over all years of award: $45,266 

Total Direct plus Indirect Costs over all years of award: $497,924 

Personal Total Direct Costs over all years of award: $23,121 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $23,121 Role  on Project: Co-Investigator. 

Description: I will oversee a prospective trial from a medical oncology perspective, including enrolling  patients, data monitoring, data analysis, and publication. Percent Effort: 5% 

Agency: Colorectal Cancer Alliance 

Identifying Number: AWD-7772985 

Title of Project: A Comparison Study of Intestinal Microbiota and Molecular Profiles of Colorectal  Cancers in Young and Older Patients (COSMO-CRC). 

Dates of Project Period: 2018-20202

Corresponding PI: Weinberg 

Total Direct Costs over all years of award: $118,000 

Total Indirect Costs over all years of award: $7,000 

Total Direct plus Indirect Costs over all years of award: $125,000 

Personal Total Direct Costs over all years of award: $0 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $0 

Role on Project: Principal Investigator. 

Description: I enroll all patients, oversee sample processing, perform data analysis, and present published  data. 

Percent Effort: n/a (no personal indirect costs). 

Agency: Victoria Casey and Peter Teeley Foundation 

Title of Project: A Comparison Study of Intestinal Microbiota and Molecular Profiles of Colorectal  Cancers in Young and Older Patients (COSMO-CRC). 

Dates of Project Period: 2018-2022

Corresponding PI: Weinberg

17

Total Direct Costs over all years of award: $50,000 

Total Indirect Costs over all years of award: $0 

Total Direct plus Indirect Costs over all years of award: $50,000 

Personal Total Direct Costs over all years of award: $0 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $0 

Role on Project: Principal Investigator. 

Description: I enroll all patients, oversee sample processing, perform data analysis, and present published  data. 

Percent Effort: n/a (no personal indirect costs). 

Agency: Ruesch Center for the Cure of Gastrointestinal Cancers 

Identifying Number: BG400772 

Title of Project: Proton Therapy in Adjuvant Pancreatic Cancer 

Dates of Project Period: 2018-2022

Corresponding PI: Weinberg 

Total Direct Costs over all years of award: $0 

Total Indirect Costs over all years of award: $25,000 

Total Direct plus Indirect Costs over all years of award: $25,000 

Personal Total Direct Costs over all years of award: $0 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $0 

Role on Project: Co-Principal Investigator. 

Description: I oversee the clinical trial from a medical oncology perspective, including enrolling patients,  data monitoring, data analysis, and publication. Percent Effort: n/a (no personal indirect costs). 

ii. Submitted (Not yet funded) 

Agency: NCI 

Identifying Number: R01 

Title of Project: Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in  Pancreatic Cancer 

Dates of Project Period: 2020-2025 

Corresponding PI: Weinberg 

Total Direct Costs over all years of award: $2,462,674 

Total Indirect Costs over all years of award: $1,276,953 

Total Direct plus Indirect Costs over all years of award: $3,739,627 

Personal Total Direct Costs over all years of award: $226,240 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $226,240 

Role on Project: Co-Principal Investigator. 

Description: I will oversee this prospective study from a medical oncology perspective, including  enrolling patients, data monitoring, data analysis, and publication. Percent Effort: 20%

18

iii. Previous

Agency: Conquer Cancer Foundation of ASCO 

Identifying Number: 2016 Young Investigator Award 

Title of Project: Combination CDK4/6 Inhibitor and mTOR Inhibitor in Metastatic Pancreatic  Adenocarcinoma 

Dates of Project Period: 2016-2017 

Corresponding PI: Weinberg 

Total Direct Costs over all years of award: $14,916 

Total Indirect Costs over all years of award: $35,084 

Total Direct plus Indirect Costs over all years of award: $50,000 

Personal Total Direct Costs over all years of award: $0 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $0 Role 

on Project: Principal Investigator. 

Description: I oversaw the clinical trial including patient enrollment, follow up, data analysis, and  publication. 

Percent Effort: n/a (no personal indirect costs). 

Agency: Private Donor via Dr. David Perry 

Title of Project: Proteomic and Genomic Analysis (PROGENY) of Pancreatic Cancer  Dates of Project Period: 2018-2020 

Corresponding PI: Weinberg 

Total Direct Costs over all years of award: $64,491 

Total Indirect Costs over all years of award: $36760 

Total Direct plus Indirect Costs over all years of award: $101,251 

Personal Total Direct Costs over all years of award: $0 

Personal Total Indirect Costs over all years of award: $0 

Personal Total Direct plus Indirect Costs over all years of award: $0 Role 

on Project: Principal Investigator. 

Description: I oversaw this retrospective biomarker trial from a medical oncology perspective,  including identifying patients, data monitoring, data analysis, and publication. Percent Effort: n/a (no  personal indirect costs). 

C. Invited Lectures: 

ASCO Annual Meeting 2021, “Novel Systemic Approaches for Metastatic Pancreatic Cancer,” Abstract  Discussant, Chicago, IL, June 2021.

Internal Medicine Board Review Course, “Medical Oncology,” Georgetown University, Washington, DC,  May 2020. 

Case Discussion, “Gastrointestinal Stromal Tumors,” School of Gastrointestinal Oncology, Oxon Hill,  MD, March 2020. 

Internal Medicine Grand Rounds, “Colorectal Cancer and the Microbiome,” MedStar Harbor Hospital,

19

Baltimore, MD, January 2020 

Lectures, “Colorectal, Pancreatic, and Upper Gastrointestinal Cancer Clinical Updates,” Pharmaceutical  Education and Research Institute (PERI), Cancer: Pathophysiology, Current Therapies, Clinical Trials,  and Drug Development Course, Washington, DC, October 2019. 

Oral Presentations, “Optimal Treatment of Stage III Colon Cancer: What is the Big IDEA?” “Targeting  Molecular Subsets in Metastatic Colorectal Cancer (dMMR, HER2, or BRAF V600E): Is it Time for  Frontline Targeted Therapy?” “Management of MSS RAS-wild type Metastatic Colorectal Cancer:  Sidedness and Anti-EGFR Retreatment,” International Society of Gastrointestinal Oncology Annual  Conference, Arlington, VA, October 2019. 

Internal Medicine Grand Rounds, “Colorectal Cancer and the Microbiome,” Georgetown University,  Washington, DC, October 2019. 

Internal Medicine Grand Rounds, “Colorectal Cancer and the Microbiome,” Veterans Affairs Medical  Center, Washington, DC, September 2019. 

Oral Presentation, “The Role of the Microbiome in Colorectal Cancer,” AllyCon, Colorectal Cancer  Alliance National Meeting, Newton, MA, September 2019. 

CME Lecture, “An Evidence-Based Individualized Approach to the Management of Gastrointestinal  Malignancies,” Med Learning Group, Washington, DC, June 2019. 

Lecture, “The Gastrointestinal Microbiome and Its Effects on Rectal Cancer and Treatment,”  Multidisciplinary International Rectal Cancer Society (MIRCS) Annual Scientific Meeting, Wynnewood,  PA, May 2019. 

Hematology/Oncology, Gastroenterology and Hepatology Combined, Grand Rounds, “Colorectal Cancer  and the Microbiome: What Our Gut is Telling Us,” Larner College of Medicine at the University of  Vermont, Burlington, VT, April 2019. 

Guest Lecture, “Colorectal Cancer and the Microbiome,” Howard University Department of  Gastroenterology, Washington, DC, March 2019. 

Internal Medicine Residency Lecture Series, “Colorectal Cancer 101,” Georgetown University,  Washington, DC, March 2019. 

CME Lecture, “Pancreatic Cancer: Metastatic Disease – Can We Do Better?” OncLive State of the  Science Summit, Gastrointestinal Malignancies, Washington, DC, February 2019. 

Lecture, “The Role of the Intratumoral Microbiome in Young Onset Colorectal Cancer,” Caris Life  Sciences Precision Oncology Alliance Annual Meeting, Grapevine, TX, December 2018. 

CME Lecture, “The Treatment Landscape for Patients with Advanced Neuroendocrine Tumors,” Ruesch  Center Symposium, Georgetown University, Washington, DC, December 2018.

20

CME Lecture, “New Advances in the Treatment of Localized and Advanced Pancreatic Cancer,” 13th Annual Georgetown Meeting on Gastrointestinal Endoscopy and Pancreaticobiliary Surgery, Washington,  DC, October 2018. 

Lectures, “Colorectal and Pancreatic Cancer Clinical Updates,” Pharmaceutical Education and Research  Institute (PERI), Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development  Course, Washington, DC, October 2018. 

Internal Medicine Grand Rounds, “Updates in Colorectal Cancer,” MedStar Harbor Hospital Department  of Medicine, Baltimore, MD, October 2018. 

Lecture, “Clinical GI Side Effects Associated with Drugs Used in the Treatment of Cancer: Mechanism,  Mitigation, and Prevention,” Safety Pharmacology Society Annual Meeting 2018, Washington, DC,  October 2018. 

Presentation, Friends of Lombardi NFL Players Association Networking Happy Hour, Washington, DC,  April 2018. 

Presentation, Colorectal Cancer Alliance ScopeItOut 5K Run Survivor and Patient Recognition and  Awards Ceremony, Washington, DC, March 2018. 

CME Lecture, “Combination CDK4/6 and mTOR Inhibition in Chemorefractory Metastatic Pancreatic  Adenocarcinoma,” Ruesch Center Symposium, Georgetown University, Washington, DC, December  2017. 

Research Seminar Guest Lecture, “Pancreatic Adenocarcinoma – New Insights into a Devastating  Disease,” George Washington University, Washington, DC, October 2017. 

Internal Medicine Grand Rounds, “Pancreatic Adenocarcinoma – New Insights into a Devastating  Disease,” MedStar Harbor Hospital, Baltimore, MD, October 2017. 

Internal Medicine Grand Rounds, “Pancreatic Adenocarcinoma – New Insights into a Devastating  Disease,” Georgetown University, Washington, DC, October 2017. 

Internal Medicine Grand Rounds, “Molecular Characterization of Squamous Cell Carcinoma of the Anal  Canal,” Georgetown University, Washington, DC, May 2017. 

Internal Medicine Grand Rounds, “Clinicopathologic Conference,” Virginia Hospital Center, Arlington,  VA, May 2014. 

Medical Student Research Forum Podium Lecture, “Image Analysis of Insulin Vesicle Exocytosis in  Pancreatic β-cells,” Keck School of Medicine of the University of Southern California, Los Angeles, CA,  May 2009. 

D. Editorships, Editorial Boards, and Reviewing Activities

Associate Editor, Gastrointestinal Cancers, Frontiers in Oncology, 2019-present.

21

Expert Panelist, ASCO Educational Book, 2018-present. 

Associate Editor, Oncology, Wiki Journal Club (www.wikijournalclub.org), 2016-present. 

Ad Hoc Reviewer: Journal of Clinical Oncology, Gut, Journal of the National Comprehensive Cancer  Network, British Journal of Cancer, Cancer Immunology Research, Gastroenterology, Clinical and  Translational Gastroenterology, American Journal of Gastroenterology, Cancer Prevention Research,  British Journal of Cancer, Cancer Medicine, Cancer Management and Research, Journal of  Immunotherapy, Journal of Comparative Effectiveness Research, Human Vaccines &  Immunotherapeutics, Journal of Immunological Sciences, Oncotargets and Therapy, Journal of Cachexia,  Sarcopenia, and Muscle, Histopathology, Future Oncology, Therapeutic Advances in Gastroenterology,  HSOA Journal of Food Science & Nutrition, and ecancermedicalscience. 

3. TEACHING, MENTORING, AND ADVISING A. Teaching Activities i. Medical School Courses Name and Course Number: OMED-110-18 

Role: Lecturer 

Number of Direct* Contact Hours: 3 

Year(s) Taught: 2019-2020 

Number of Students: Entire 2nd year medical school class 

Overall Evaluation Score: n/a 

ii. Medical School Clerkships Name 

of Clerkship: Internal Medicine 

Role: Bles 2 Teaching Attending 

Number of Direct Contact Hours*: 32 

Year(s) Taught: 2018-2019 

Number of Students/Fellows: 6 per year 

Overall Evaluation Score: n/a 

Average number of Clinical Fellows you train per year = 12 Average 

number of Residents you train per year = 5 

Average number of Medical students you train per year = 8 

iii. Graduate Biomedical Education Courses 

Name and Course Number: TBIO-511 

Role: Lecturer 

Number of Direct* Contact Hours: 4 

Year(s) Taught: 2018-2020

22

Number of Students: 14 per year 

Overall Evaluation Score: 57.2/60 

Average number of Postdoctoral Fellows you train per year = 0 

Average number of Graduate students you train per year = 14 

B. Mentoring:

Mentor: 

Name of Mentee: Reetu Mukherji 

Dates of Mentorship: 2019-2020 

Outcomes: Colorectal Cancer Review Article (1st author) 

Name of Mentee: Samantha A. Armstrong 

Dates of Mentorship: 2019-2020 

Outcomes: Oncology & Hematology Review Article (1st author) Name of Mentee: Rita Malley  Dates of Mentorship: 2019-2020 

Outcomes: Oncology & Hematology Review Article (2nd author) 

Name of Mentee: Bhavana P. Singh 

Dates of Mentorship: 2018-2020 

Outcomes: 2020 Gastrointestinal Cancers Symposium Poster (1st author) 

Name of Mentee: Madison Ballman 

Dates of Mentorship: 2019 

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (2nd author) 

Name of Mentee: Evan Drake 

Dates of Mentorship: 2019 

Outcomes: 2020 Gastrointestinal Cancers Symposium Poster (3rd author) 

Name of Mentee: Ashish Khanchandani 

Dates of Mentorship: 2019 

Outcomes: 2020 Gastrointestinal Cancers Symposium Poster (4th author) 

Name of Mentee: Michael R. Lindberg 

Dates of Mentorship: 2019 

Outcomes: Journal of Gastrointestinal Oncology Original Research Article (3rd author) 

Name of Mentee: Allison Doyle 

Dates of Mentorship: 2018-2020 

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (1st author) 

Name of Mentee: Manfred Kubler 

Dates of Mentorship: 2018-2019

23

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (2nd author) 

Name of Mentee: Ashton Harris 

Dates of Mentorship: 2018 

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (3rd author) 

Name of Mentee: Alfredo López 

Dates of Mentorship: 2018 

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (4th author) 

Name of Mentee: Prateek Govindaraj 

Dates of Mentorship: 2018 

Outcomes: 2019 Gastrointestinal Cancers Symposium Poster (5th author) 

Name of Mentee: Michael T. Serzan 

Dates of Mentorship: 2017 

Outcomes: Current Colorectal Cancer Reports Review Article 

Name of Mentee: Jeevan M. Puthiamadathil 

Dates of Mentorship: 2017 

Outcomes: Cancer Management and Research Review Article 

Name of Mentee: Neel Trivedi 

Dates of Mentorship: 2017-2020 

Outcomes: 2018 ASCO Annual Meeting Poster (1st author) 

4. SERVICE 

A. University Service:

i. Department 

Clinical Trials Protocol Writing Seminar Series Director, Georgetown University Medical Center,  Washington, DC, 2016-present 

Summer Student Program Mentor, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown  University Medical Center, 2018-present 

ii. School

Discussion Panelist, End of Life Discussion Panel, Pediatrics-Geriatrics Course, Georgetown University  School of Medicine, 2018 

Judge, George M. Kober Student Research Day, Georgetown University School of Medicine, 2018  iii. University 

Member, Research Integrity Committee, Georgetown University Medical Center, 2019-present Member,  Clinical Review Committee, Georgetown University Medical Center, 2017-present

24

B. MedStar or Hospital Service

Chair, Clinical Competency Advisory Committee, Hematology and Oncology Fellowship Program,  MedStar Georgetown University Hospital, 2018-present 

Member, Clinical Competency Advisory Committee, Hematology and Oncology Fellowship Program,  MedStar Georgetown University Hospital, 2017-present 

Applicant Interviewer, Hematology and Oncology Fellowship Program, MedStar Georgetown University  Hospital, 2017-present 

Applicant Interviewer, Internal Medicine Residency Program, MedStar Georgetown University Hospital,  2017-2018 

Education Council, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,  Washington DC, 2016-2017 

C. Professional Service: 

ASCO Question Writing Group Member, 2021-present

ASCO Virtual Mentoring Program Member, 2020-present

ASCO Educational Book Reviewer, 2020-present

Speaker and Panelist, Hope Connections Ruesch Center Gastrointestinal Cancer Patient Summit, 2017- 2018 

Judge, AACR Annual Undergraduate Student Caucus and Poster Competition, Washington, DC, April  2017 

Volunteer, ASCO Volunteer Corps, Alexandria, VA, 2017-present 

5. HONORS AND AWARDS 

Castle Connolly / Washingtonian Top Doctor, Washington, DC, November 2022 HemeOnc Today’s Next Gen Innovator, June 2019 

First Place, Fellow Clinical Research Award, Georgetown Department of Medicine Research Day, May  2017 

Conquer Cancer Foundation Gastrointestinal Cancers Symposium Merit Award, January 2017  Conquer Cancer Foundation of ASCO Young Investigator Award, June 2016 

AACR/ASCO Workshop on Methods in Clinical Cancer Research Invited Participant, Vail, CO, 2015  Walker Foundation Scholarship, 2009-2010 

Achievement Rewards for College Scientists (ARCS) Foundation Scholarship, 2009-2010  Donald E. and Delia B. Baxter Foundation Award, 2009 

Medical Student Summer Research Fellowship, Keck School of Medicine, 2008  Dean’s Recognition, Keck School of Medicine, 2007-2009 

NIH Summer Intramural Research Training Award Fellowships, 2004-2006 

6. PROFESSIONAL SOCIETY MEMBERSHIP 

Fellow, American College of Physicians, 2020-present 

Member, American College of Physicians, 2008-present

Member, American Association for Cancer Research, 2017-present

25

Member, American Society of Clinical Oncology, 2014-present 

Member, American Society of Hematology, 2014-present